DeutschNewstral
Article
Seattle Times on 2019-05-31 02:15
Adaptive Biotech seeks $230 million in IPO
Related news
Seattle biotech Adaptive buys San Francisco firmseattletimes.com- Adaptive Biotech hires CFO who helped Zilllow go publicseattletimes.com
- MAdaptive Biotechnologies CEO Chad Robins on that crazy IPO and working with his older brothermarketwatch.com
- Adaptive Biotechnologies raises $195 million in venture fundingseattletimes.com
Davis biotech company Arcadia Biosciences seeks IPO to raise $86Mbizjournals.com- Seattle’s next big biotech, Adaptive Biotechnologies, seeks more space in Lake Union areabizjournals.com
- Shares of Adaptive Biotechnologies leap after Seattle firm’s IPOSeattle Times
- Seattle biotech Silverback Therapeutics prices upsized IPOseattletimes.com
- San Francisco biotech CytomX files for $100 million IPObizjournals.com
- MAdaptive Biotechnologies sets terms for IPO, to raise up to $212.5 millionmarketwatch.com
- Seattle biotech Adaptive lives up to its name, pivots toward drug developmentbizjournals.com
- Seattle biotech firm Silverback Therapeutics aims for $100M IPOSeattle Times
- Adaptive Bio raises $94 million, buys Bay Area's Sequentabizjournals.com
- Seattle biotech PhaseRx prices IPO at $5 a shareseattletimes.com
- MAdaptive Biotechnologies IPO: Five things to knowmarketwatch.com
- MCardlytics seeks to raise $75 million in IPOmarketwatch.com
- MSienna Biopharmaceuticals seeks to raise $74.8 million in IPOmarketwatch.com
- M5 things to know about biotech Denali Therapeutics and its $250 million IPOmarketwatch.com
- MPediatric cancer biotech Y-mAbs Therapeutics raises $96 million in IPOmarketwatch.com
- MBiotech Arvinas to offer 6.7 million shares in IPO priced at $14 to $16 eachmarketwatch.com